Ildong Pharmaceutical Statistics

Total Valuation

Ildong Pharmaceutical has a market cap or net worth of KRW 410.61 billion. The enterprise value is 564.44 billion.

Market Cap	410.61B
Enterprise Value	564.44B

Important Dates

The next estimated earnings date is Thursday, October 31, 2024.

Earnings Date	Oct 31, 2024
Ex-Dividend Date	n/a

Share Statistics

Ildong Pharmaceutical has 27.93 million shares outstanding. The number of shares has increased by 3.05% in one year.

Shares Outstanding	27.93M
Shares Change (YoY)	+3.05%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.42%
Owned by Institutions (%)	3.74%
Float	16.12M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.67
PB Ratio	2.51
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 78.35, with an EV/FCF ratio of -30.08.

EV / Earnings	-11.60
EV / Sales	0.93
EV / EBITDA	78.35
EV / EBIT	n/a
EV / FCF	-30.08

Financial Position

The company has a current ratio of 0.77, with a Debt / Equity ratio of 1.26.

Current Ratio	0.77
Quick Ratio	0.42
Debt / Equity	1.26
Debt / EBITDA	30.12
Debt / FCF	-11.56
Interest Coverage	-1.17

Financial Efficiency

Return on equity (ROE) is -30.55% and return on invested capital (ROIC) is -3.08%.

Return on Equity (ROE)	-30.55%
Return on Assets (ROA)	-1.92%
Return on Capital (ROIC)	-3.08%
Revenue Per Employee	592.02M
Profits Per Employee	-47.72M
Employee Count	1,020
Asset Turnover	0.97
Inventory Turnover	3.80

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.44% in the last 52 weeks. The beta is 0.93, so Ildong Pharmaceutical's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	-21.44%
50-Day Moving Average	14,707.20
200-Day Moving Average	15,101.85
Relative Strength Index (RSI)	51.58
Average Volume (20 Days)	98,797

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ildong Pharmaceutical had revenue of KRW 603.86 billion and -48.68 billion in losses. Loss per share was -1,783.29.

Revenue	603.86B
Gross Profit	220.07B
Operating Income	-19.20B
Pretax Income	-55.09B
Net Income	-48.68B
EBITDA	7.20B
EBIT	-19.20B
Loss Per Share	-1,783.29

Full Income Statement

Balance Sheet

The company has 70.91 billion in cash and 216.99 billion in debt, giving a net cash position of -146.08 billion or -5,229.83 per share.

Cash & Cash Equivalents	70.91B
Total Debt	216.99B
Net Cash	-146.08B
Net Cash Per Share	-5,229.83
Equity (Book Value)	171.55B
Book Value Per Share	5,864.08
Working Capital	-72.04B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -5.72 billion and capital expenditures -13.04 billion, giving a free cash flow of -18.77 billion.

Operating Cash Flow	-5.72B
Capital Expenditures	-13.04B
Free Cash Flow	-18.77B
FCF Per Share	-671.86

Full Cash Flow Statement

Margins

Gross margin is 36.44%, with operating and profit margins of -3.18% and -8.06%.

Gross Margin	36.44%
Operating Margin	-3.18%
Pretax Margin	-9.12%
Profit Margin	-8.06%
EBITDA Margin	1.19%
EBIT Margin	-3.18%
FCF Margin	-3.11%

Dividends & Yields

Ildong Pharmaceutical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.05%
Shareholder Yield	-3.05%
Earnings Yield	-12.13%
FCF Yield	-4.57%

Stock Splits

The last stock split was on March 5, 2020. It was a forward split with a ratio of 1.05.

Last Split Date	Mar 5, 2020
Split Type	Forward
Split Ratio	1.05

Scores

Ildong Pharmaceutical has an Altman Z-Score of 1.23. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.23
Piotroski F-Score	n/a